Emricasan

DRUG4 trials

Sponsors

Histogen, Meridian Bioscience, Inc.

Conditions

CirrhosisCovid19Decompensated CirrhosisNASH - Nonalcoholic SteatohepatitisNon-alcoholic SteatohepatitisPortal Hypertension

Phase 1

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

TerminatedNCT04803227

HistogenCovid19

Start: 2021-03-11End: 2021-05-28Updated: 2022-01-04

Phase 2

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

CompletedNCT02960204

HistogenCirrhosis, Non-alcoholic Steatohepatitis, Portal Hypertension

Start: 2016-10-17End: 2019-04-08Updated: 2022-02-11

Unknown Phase

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

CompletedNCT03439189

Meridian Bioscience, Inc.Cirrhosis, NASH - Nonalcoholic Steatohepatitis, Portal Hypertension

Start: 2016-08-28End: 2019-05-13Updated: 2022-12-20

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

TerminatedNCT03462576

Meridian Bioscience, Inc.Decompensated Cirrhosis

Start: 2017-06-28End: 2019-07-15Updated: 2022-12-20

Related Papers

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.

2019-12-21118 citations